CDC recommendations for influenza antiviral medications remain unchanged

Details

• Corporate Authors:
  Centers for Disease Control and Prevention (U.S.)
• Description:
  February 09, 2012, 15:00 EST
  
  CDCHAN-00324-ADV-N
  
  A recent review of randomized clinical trial data for the influenza neuraminidase inhibitor antiviral medications, and two related commentaries, raised questions about the value of antiviral medications for the prevention and treatment of influenza. On February 7, 2012, the Centers for Disease Control and Prevention (CDC) posted a "Have You Heard?" piece in response. The CDC response states "After careful consideration of all available evidence, CDC guidance on the use of antiviral medications remains unchanged." CDC continues to recommend the use of neuraminidase inhibitor antiviral drugs (oral oseltamivir and inhaled zanamivir) as an important adjunct in the prevention and treatment of influenza.
  
  
• Subjects:
  Antiviral Agents Influenza, Human/drug Therapy Influenza, Human/prevention & Control Oseltamivir Zanamivir
• Source:
  HAN ; 324
• Series:
  Health Alert Network
• Document Type:
  HAN Info Service
• Pages in Document:
  2 unnumbered pages
• Issue:
  324
• Collection(s):
  Health Alert Network (HAN)
• Main Document Checksum:
  urn:sha-512:016847be3267d6d8ae78de390a0e623cb65fdc7ff16bf304c2b69b1751afe54d1302380455cbd6f9d47c7fd28db273cdc4aa31f9277d9a35b16eaf8164cdbcfb
• Download URL:
  https://stacks.cdc.gov/view/cdc/25233/cdc_25233_DS1.pdf
• File Type:
  [PDF - 1.36 MB ]